---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-108315"
form_type: "8-K"
ticker: "INMB"
cik: "0001711754"
company_name: "Inmune Bio, Inc."
filed_at: "2025-11-10T23:59:59+00:00"
generated_at: "2026-05-16T22:28:50.615827+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# INmune Bio: CORDStrom MAA mid-2026, XPro Phase 3 in 2027; $30M cash as of Oct 14

## Summary
- CORDStrom Phase 2 in RDEB improves itch/pain; MAA to UK MHRA mid-2026, BLA in US late-2026.
- XPro1595 Phase 2 in early AD halts cognitive decline in biomarker-enriched patients; zero ARIA cases.
- End-of-Phase-2 FDA meeting for XPro in Q1 2026; Phase 3 start planned for 2027.
- Cash $30M as of Oct 14, 2025; market cap ~$50M; ~26.5M shares outstanding.
- CORDStrom has Rare Pediatric Disease and Orphan Drug designations; potential PRV.

## SEC filing metadata
- accession: 0001213900-25-108315
- form_type: 8-K
- ticker: INMB
- cik: 0001711754
- company_name: Inmune Bio, Inc.
- filed_at: 2025-11-10T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1711754/000121390025108315/0001213900-25-108315-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1711754/000121390025108315/ea0264915-8k_inmune.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-108315
- JSON: https://secwatch.observer/filing/0001213900-25-108315.json
- Plain text: https://secwatch.observer/filing/0001213900-25-108315.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.